Depomed has acquired US and Canadian rights to Archimedes Pharma’s Lazanda (fentanyl) nasal spray for $4m in cash for pain management in cancer patients (BTPc) 18 years of age and older.
Leveraging Archimedes patented PecSys drug delivery system, the product is indicated for patients who are tolerant and receiving opioid therapy for the underlying persistent cancer pain.
Designed to deliver a fine mist spray to the nasal membrane, Lazanda delivers a Schedule 2 controlled substance, fentanyl, in a rapid and controlled manner.
Upon contact to nasal mucosa, each spray of Lazanda forms a gel and the active ingredient is then rapidly absorbed across the mucus membrane and directly into the blood stream.
Archimedes is eligible for sales-based royalties, potential milestone payments based on increased sales of Lazanda and assumption of certain liabilities.
Depomed president and CEO Jim Schoeneck said, "We believe that Lazanda is differentiated in the breakthrough cancer pain space, allowing rapid onset of effect and avoiding administration of drug across the oral mucosa, which can be a challenge in some cancer patients."
